Medical Health & Life Science Research News

New report examines the raynauds disease pharmaceutical & healthcare pipeline assessment

Medical Market Research

HTF Market Intelligence released a new research report of 49 pages on title 'Raynauds Disease - Pipeline Review, H1 2017' with detailed analysis, forecast and strategies. The study covers key regions and important players such as Allergan Plc, Apricus Biosciences Inc, Covis Pharmaceuticals Inc ..................

The latest Pharmaceutical and Healthcare disease pipeline guide Raynauds Disease - Pipeline Review, H1 2017, provides an overview of the Raynauds Disease (Cardiovascular) pipeline landscape.

Raynauds disease is a common condition that affects the blood supply to certain parts of the body, usually the fingers and toes. Predisposing factors include age, gender, family history and smoking.

Symptoms include fingers, toes, ears, or nose to become white, and then turn blue.

Treatment includes vasodilator, alpha blockers and calcium channel blockers.


 Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Raynauds Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Raynauds Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Raynauds Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Raynauds Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively.

Similarly, the Universities portfolio in Unknown stages comprises 1 molecules, respectively.

Raynauds Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


- The pipeline guide provides a snapshot of the global therapeutic landscape of Raynauds Disease (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Raynauds Disease (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Raynauds Disease (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Raynauds Disease (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Raynauds Disease (Cardiovascular)

Reasons to access

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Raynauds Disease (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Raynauds Disease (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Table of Contents

List of Tables

List of Figures


Global Markets Direct Report Coverage

Raynauds Disease - Overview

Raynauds Disease - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Raynauds Disease - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Raynauds Disease - Companies Involved in Therapeutics Development

Allergan Plc

Apricus Biosciences Inc

Covis Pharmaceuticals Inc

Human Stem Cells Institute

Raynauds Disease - Drug Profiles

alprostadil - Drug Profile

Product Description

Mechanism Of Action

 View Detailed Table of Content at…e-pipeline-review



This email address is being protected from spambots. You need JavaScript enabled to view it.